Live
- A Guide to Temperature and Humidity Standards in Data Center Server Rooms
- Gadwal collector briefs on details of voters
- Jupally Krishna Rao takes part in Alampur rallu
- Bharath Prasad files 3rd Nomination
- Baisakh Month: A Time of Auspicious Beginnings and Sacred Festivals
- Oust BJD govt for overall development, says Shah
- Unveiling the Hidden Gems: Surprising Health Benefits of Garlic Peels
- Overcoming Sleep Struggles: A Comprehensive Guide to a Restful Night
- RTC bus hit the auto
- MLA Kuchukula Rajesh Reddy participated in the Birappa festival
Shantha Bio to produce Sonafi’s Insuman in Hyd
Homegrown Shantha Biotechnics, a biotech pioneer acquired by French Sanofi Pasteur Holding in 2009, is all set to enter human insulin market in a big way.
Cost of the plant estimated at Rs.460 crore; Commercial operations to start from 2019
Hyderabad: Homegrown Shantha Biotechnics, a biotech pioneer acquired by French Sanofi Pasteur Holding in 2009, is all set to enter human insulin market in a big way.
The company is setting up state-of-the-art facility to manufacture human insulin for diabetes patients at its Muppireddipalli location, about 30 kms from the city.
Speaking at the foundation laying ceremony, Shantha’s CEO, Dr Harish Iyer said the parent Sanofi is investing Rs 460 crore in the project. “This plant will be Sanofi’s second Insulin manufacturing plant outside Frankfurt.”
The construction activity will commence soon and the facility will be operational by 2019, Iyer said and added that the facility is expected to meet the local and international demand. Speaking after laying the foundation stone for the plant, the Telangana Chief Minister K Chandrashekar Rao assured the promoter Dr Varaprasad Reddy of full support to the project. “My government is committed to supporting the industry and very shortly the industrial policy is being announced,” he reiterated.
Rao said the government is waiting for the division of the officers, which is the duty of the Centre. “Now that the allotment of officers is over and concerned officers are taking respective charges, we will announce the industrial policy soon,” he pointed out.
Iyer said, for the first time, the company will manufacture insulin in cartridges; a newer technology that enhances the production expertise of the company.
“This facility will have the capability to ramp up manufacturing volumes to 60 million Insuman cartridges per year, within two to three years of commercial production.”
Sanofi India Managing Director Dr Shailesh Ayyangar linked the project to the PM’s Make in India programme and said the technology transfer and collaborative effort of the Sanofi Group will surely address the growing epidemic of diabetes in India.
The type-2 diabetes globally afflicts close to 382 million people and in India alone there known cases accounting to 65 million and not identified would be in the order of about 100 million. According to statistics, the number of afflicted people in India would swell to over 100 million by 2035.
The company produces WHO licensed vaccines including Shan5 (pediatric vaccine), Shanchol (cholera vaccine), Shanvac-B (hepatitis B vaccine) and ShanTT (tetanus vaccine), besides it also produces Sanofi Pasteur and polio vaccine.
